📅 PUBMED DAILY TRIAGE — 2026-04-27
Window: 2026-04-26T09:00:00Z → 2026-04-27T09:00:00Z (CRDT)
Topics scanned: 9 | Articles reviewed: ~90 candidates (incl. 56 deferred)
High priority: 1 | Standard: 14 | Low/archive: 3 | Unsolicited finds: 0
Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Novel Therapeutics / Hematologic Malignancies (CAR-T)
TR-2026-04-27-001 / PMID 42036693 · Five-year follow-up of R/R MCL patients treated with anti-CD19 CAR T-cell therapy in ZUMA-2 · 9/10 🟠 NOVEL_TREATMENT
Pivotal ZUMA-2 5-year data (N=68) confirms brexu-cel (anti-CD19 CAR-T) delivers durable survival in relapsed/refractory MCL: median OS 46.5 months, DOR 36.5 months, and no late safety signals (no T-cell malignancies), supporting continued use of the only approved CAR-T for MCL.
🟢⚪ STANDARD (5-7) — Top by Topic
Precision Oncology / Genomic Medicine
TR-2026-04-27-002 / PMID 42036313 · TMB predicts ICI response in HNSCC: systematic review & meta-analysis · 7/10 · Diagnostics
17 cohorts, n=1,472; high TMB → OR=2.80 for ORR, HR=0.58 for OS; bTMB requires ≥16 mut/Mb threshold vs. tTMB ~10 mut/Mb. Clinically actionable for liquid biopsy TMB testing in HNSCC.
Population Health / Aging
TR-2026-04-27-003 / PMID 42033061 · Allostatic load & incident CRC in multiethnic Asian cohort · 6/10 · Prevention
N=30,443 prospective, 162 CRC cases, median follow-up 7.2y; high allostatic load → aHR=1.53 (95%CI 1.10-2.14) for CRC risk. First large Asian multiethnic validation of allostatic load as CRC risk biomarker. [Deferred PMID, now resolved]
Hematologic Malignancies
TR-2026-04-27-004 / PMID 42032835 · Socioeconomic disparities in multiple myeloma survival, NSW Australia (N=6,030) · 6/10 · Public Health
Low SES → 27% higher MM mortality excess risk; mostly mediated by ASCT access and hospital type. Actionable equity implications. [Deferred PMID, now resolved]
Cardiovascular-Metabolic
TR-2026-04-27-005 / PMID 42036722 · Metabolic syndrome score trajectory patterns & cardiometabolic multimorbidity (CHARLS) · 5/10 · Prevention
K-means clustering of longitudinal MetSyn scores identifies dynamic trajectory patterns predicting cardiometabolic multimorbidity progression; physical activity modulates risk.
TR-2026-04-27-006 / PMID 42036685 · LDL-C + Chinese visceral adiposity index for cardiometabolic risk stratification (national prospective) · 5/10 · Diagnostics
Combined biomarker tool improves cardiometabolic multimorbidity risk prediction over individual markers in Chinese national cohort.
Early Cancer Detection / cfDNA
TR-2026-04-27-007 / PMID 42036438 · cfDECOR: cell type deconvolution of cfDNA via chromatin accessibility patterns · 5/10 · Early Detection
Novel computational method using ATAC-seq fragmentomics for cfDNA tissue-of-origin deconvolution; exploratory but methodologically novel for multi-cancer liquid biopsy.
AI/ML in Diagnostics
TR-2026-04-27-008 / PMID 42036650 · AI-enabled smartphone obstetric ultrasound in Sierra Leone · 5/10 · Diagnostics / Underserved
Mixed-methods study showing usability and practicality of AI ultrasound for task-shifting in LMIC maternal care; addresses critical diagnostic gap in underserved settings.
TR-2026-04-27-009 / PMID 42036745 · Fibroblast senescence ML classification for Alzheimer's disease (n=26) · 5/10 · Diagnostics
ML classifiers at mid-old senescence stage achieve >90% AD accuracy; 3 genes correlated with amyloid burden and pTau217. Novel peripheral senescence biomarker approach.
TR-2026-04-27-010 / PMID 42036629 · LncRNA PCAT18 review in human cancers including leukemia · 4/10 · Genomics/Precision Medicine
TR-2026-04-27-011 / PMID 42036664 · ADC evolution in breast cancer: TME reprogramming (J Hematol Oncol review) · 4/10 · Treatment Innovation
TR-2026-04-27-012 / PMID 42036675 · TILs in TNBC: molecular mechanisms and therapeutic implications (review) · 4/10 · Treatment Innovation
TR-2026-04-27-013 / PMID 42036673 · MXene-CRISPR/Cas9 nanoplatform for cervical cancer PDT (~96% inhibition, preclinical) · 4/10 · Drug Development
TR-2026-04-27-014 / PMID 42036643 · CKM syndrome multidimensional biomarker system + AI review · 4/10 · Diagnostics
TR-2026-04-27-015 / PMID 42032842 · CRC peritoneal metastasis FGFR3 stromal axis + FGFR inhibitor (preclinical) · 4/10 · Drug Development
💡 UNSOLICITED FINDS
No out-of-watchlist high-signal items qualified this run. Sentinel scan (475 raw, 10 reviewed) yielded no articles surpassing STANDARD threshold outside existing watchlist coverage.
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 4 (incl. 1 HIGH)
- Diagnostics: 5
- Prevention: 3
- Drug Development: 2
- Early Detection: 1
- Genomics/Precision Medicine: 1
- Public Health: 1
- Other: 1
By evidence maturity:
- Validated: 4 (PMID 42036693, 42036313, 42033061, 42032835)
- Exploratory: 14
By watchlist topic (reviewed / kept / highest score):
| Topic | Reviewed | Kept | Highest Score |
|---|---|---|---|
| Hematologic malignancies | 10 | 4 | 9 ✅ |
| CBC/ML hematology | 1 | 0 (deferred) | N/A |
| Early cancer detection (liquid biopsy, ctDNA) | 10 | 2 | 5 |
| AI/ML in diagnostics | 10 | 3 | 5 |
| Precision oncology / genomics | 10 | 1 | 7 |
| Novel therapeutics | 10 | 4 (overlap) | 9 |
| Cardiovascular-metabolic | 10 | 3 | 5 |
| Aging / longevity | 10 | 2 | 6 |
| Rare diseases | 10 | 1 | 3 |
By source type: peer_reviewed: 18 | preprint: 0
Topics with zero 8+ articles this run: CBC/ML hematology, Early cancer detection, AI/ML diagnostics, Cardiovascular-metabolic, Aging/longevity, Rare diseases, Precision oncology
🔧 RUN NOTES
- Window expansion: Not triggered (18 relevant articles classified without expansion).
- Deferred PMID resolution: All 56 deferred PMIDs from 2026-04-26 run were re-reviewed. 2 resolved to STANDARD (PMID 42032835, 42033061), 1 to LOW (42033074), 1 to STANDARD (42032842). Remaining 52 were off-topic or below triage threshold.
- CBC/ML hematology topic: 1 raw result (PMID 42035021), abstract not retrieved — deferred to 2026-04-28. This is the fourth consecutive sparse run for this topic. Recommended action: broaden query to include hematology differential + CBC + AI/neural network, or expand to morphology/blood smear AI.
- Truncation: AI/ML diagnostics (69 hits), cardiovascular-metabolic (78 hits), aging (161 hits), sentinel (475 hits) all capped at 10. Strictly adherent to per-topic cap policy; most excluded articles were off-watchlist.
- Sentinel scan: 475 raw results; 10 reviewed; 0 unsolicited finds above STANDARD threshold.
- No previously emitted fingerprints were re-emitted (all PMID 42036693+ are new).
- Rolling 7-day sparse topics: CBC/ML hematology has been consistently sparse for 4+ consecutive days. Precision oncology produced 1 STANDARD this run (improvement vs prior 0).